Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

Humm Group Limited ( ($AU:HUM) ) has shared an update. Humm Group Limited has notified the market of the cessation of certain performance rights un...

Humm Group Adjusts Capital Structure as Performance Rights Lapse

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Humana (HUM) and Krystal Biotech (KRYS) with bullish...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Humana AB ( ($SE:HUM) ) has shared an update. Humana AB reported modest top-line growth for the second quarter of 2026, with net revenue up 3 perce...

Humana boosts profitability and cash flow despite muted growth in Q2 2026

In a report released today, Ann Hynes from Mizuho Securities maintained a Buy rating on Humana, with a price target of $468.00. Hynes covers the He...

Mizuho Securities Keeps Their Buy Rating on Humana (HUM)

Ord Minnett analyst Phillip Chippindale maintained a Buy rating on Humm Group Limited today and set a price target of A$0.75. According to TipRanks...

Humm Group Limited (F5L) Gets a Buy from Ord Minnett

An update from Humm Group Limited ( ($AU:HUM) ) is now available. Humm Group has announced that The Abercrombie Group has decided not to proceed, f...

Humm Group Faces Delay in Board Nomination from Abercrombie Group

The latest update is out from Humm Group Limited ( ($AU:HUM) ). Humm Group Limited has disclosed that the Australian Securities and Investments Com...

ASIC Concludes Humm Group Probes Without Enforcement Action

An update from Humana AB ( ($SE:HUM) ) is now available. Humana’s board has unanimously recommended that shareholders accept Ambea AB’s public take...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$389.32	-1.31%	740.29K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$389.32	-1.3%	740.29K
3
4
5
6

HUM

HUM

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel